• FR
  • Inform me about new class actions

    • This field is for validation purposes and should be left unchanged.

    Coming soon

    Notice about our registration form
    Completing the form does not guarantee you any compensation

    Please note that completing this form does not guarantee you any compensation.

    Indeed, it will ultimately be up to the court to decide on the merits of the class action and the terms of compensation. In addition, the eligibility criteria to receive compensation could be modified by the court, which could result in your exclusion from the class action.

    Please also note that we will not conduct a detailed analysis of each individual case until there is a final judgment or settlement in the file. Completing this form does not mean that you are eligible.

    We will inform the people who have registered of any final outcome in the class action. We will communicate with them by email. We invite you to notify us of any changes to your email address.

    We also invite you to keep informed through our website which we will update regularly.

    We thank you for your interest in this class action.


    Completed class actions

    Groupe d'action d'investisseurs dans Biosyntech v. Joyce Tsang, Karen Hong, Eric Linsley, Somesh Sharma, Jeanne Bertonis, Rudy Huber, André Archimbaud, and Jean-Pierre Desmarais

    BioSyntech Inc.

    The Case

    On May 13, 2013, Mr. Vincent Blais, represented by Trudel Johnston & Lespérance (TJL), launched a Class action against the eight members of the Board of Directors of BioSyntech Inc. as of May 12, 2010. You can consult the Motion to institute a Class Action filed in front of the Superior Court of Québec here.

    The Class was defined as follows:

    All natural persons and legal persons which, in the 12 months previous to May 13 2013, had fewer than 50 employees, who held securities of BioSyntech Inc. on May 12, 2010, except the Respondents, ProQuest Investments LLP, Fonds de Solidarité des Travailleurs du Québec, Pappas Ventures, Nicholas Piramal India Limited, and Highland Capital Management;

    The Respondent Directors of BioSyntech Inc. oversaw a troubling pattern of negligence that resulted in the sale of its intellectual property and the subsequent bankruptcy of the company, when it was on the verge of completing pivotal, stage Ill, clinical results for its promising, flagship medical device to repair damaged knee cartilage. After having taken a risk and invested in a promising biotechnology start up, securities holders were deprived of the fruits of their investment by the negligence of the Respondents.

    On May 19, 2010, Piramal, a shareholder in BioSyntech that was represented by Respondent Somesh Sharma on the Board, bought BioSyntech’s core assets, including the patents for BST-CarGel, for $4,556,000.

    The proposed Class action seeks compensatory damages for the losses suffered by security holders of Biosyntech Inc. when its Directors, the Respondents, authorized the company to seek bankruptcy protection on May 12, 2010.


    On June 30, 2015, Justice Hamilton of the Superior Court of Québec dismissed the Motion for authorization to institute a Class action. This judgment can be found here.

    On July 30, 2015, TJL appealed Justice Hamilton’s decision. TJL’s Inscription in appeal can be found here.

    On November 30, 2016, the Court of Appeal dismissed TJL’s appeal. This judgment can be found here.

    Following the Court of Appeal’s decision, this class action has come to an end.